Measurements of sCD40L in patients who are enrolled in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial showed that higher levels of sCD40L increased the risk of recurrent strokes in comparison to the lower levels of sCD40L in patients. This evidence concerns the gene CD40LG and Stroke.